Investigators compared the safety and efficacy of polatuzumab vedotin with or without rituximab, gemcitabine, and oxaliplatin in first line for patients with relapsed/refractory diffuse large B-cell ...

In this analysis, researchers examined long-term outcomes for EWS survivors based on chemotherapy regimen, as well as compared to siblings and the general population.

In this long-term follow-up to the phase 2 ARTO trial, researchers analyzed survival outcomes in patients with CRPC treated with metastasis-directed therapy.

Rates of prostate cancer screening shared decision-making (SDM) are very low in family medicine practices, according to a study published in the June issue of the Southern Medical Journal. Nicholas ...

A quality improvement study analyzed the value of advanced telehealth delivery methods during prostate cancer management.

Investigators in this retrospective cohort study sought to determine long-term outcomes for patients with platinum-sensitive recurrent ovarian cancer who have exceptional response to PARP inhibitors.

Using individual patient data from phase 2 and 3 trials, investigators analyzed the value of pathologic complete response vs ctDNA clearance after neoadjuvant immunotherapy or perioperative ...

ASCO's 2026 annual conference in Chicago featured cutting-edge research on treatment strategies for sarcomas such as GIST and ...

Investigators compared trial demographics against baseline electronic health record data at 3 NCI–designated cancer centers to identify enrollment gaps.

The Stockholm3 model combines PSA, plasma protein biomarkers, polygenic risk, and clinical factors for prostate cancer screening.

Investigators conducted a retrospective analysis to determine whether postmenopausal women with a history of breast cancer can safely receive vaginal estrogen.

In the phase 3 SUBITO trial, researchers aimed to compare outcomes with intensified alkylating chemotherapy to those with an HRD-targeting regimen.